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Leptin activates its cognate receptor (LR) to regulate
body weight and metabolically costly processes,
such as reproduction and immune responses.
Despite such benevolent pleiotropy, leptin-mediated
signaling has been implicated in autoimmune dis-
eases and breast cancer, thereby rejuvenating
interest in leptin antagonism. We present compara-
tive biochemical and structural studies of the LR
ectodomain (LRecto) in complex with wild-type and
antagonist leptin variants. We show that high-affinity
binding of leptin to the cytokine receptor homology 2
domain of LRecto primes interactions with the
Ig-domain (LRIg) of another leptin-bound LRecto to
establish a quaternary assembly. In contrast, antag-
onist leptin variants carrying mutations at the LRIg
binding site only enable binary complexes with
LRecto. Acetylation of free cysteines in LRecto also
abrogates quaternary complexes, suggesting a func-
tional role for intrareceptor disulfides. We propose a
revised conceptual framework for LR activation
whereby leptin activates predimerized LR at the cell
surface to seed higher order complexes with 4:4
stoichiometry.
INTRODUCTION
Leptin receptor (LR), a type I cytokine receptor, is activated by
its cognate ligand leptin secreted by the adipose tissue to
regulate a host of essential body functions, such as the homeo-
stasis of body weight and energy (Friedman and Halaas, 1998;
Halaas et al., 1995; Varela and Horvath, 2012), the immune
system and hematopoiesis (Carbone et al., 2012; Procaccini
et al., 2012), reproduction and fetal development (Hausman
et al., 2012), angiogenesis (Cao et al., 2001; Park et al.,
2001), and bone formation (Motyl and Rosen, 2012). Leptin-
mediated activation of LR signals through the Janus kinase
(JAK)/signal transducer and activator of transcription (STAT)866 Structure 22, 866–877, June 10, 2014 ª2014 Elsevier Ltd All righpathways and also modulates the activity of phosphoinosi-
tide 3-kinase, mitogen-activated protein kinase, extracellular
signal-related kinase, and AMP-activated protein kinase (Wau-
man et al., 2008). The pleiotropic signaling via the leptin-LR axis
and its potential in treating a number of pathologies have been
a cynosure for more than a decade. Although leptin mono-
therapy has been ineffective to curb obesity, it has found appli-
cations in type 1 and type 2 diabetes (Cummings et al., 2011;
Wang et al., 2010), in rare cases of congenital leptin deficiency
(Ramachandrappa and Farooqi, 2011), as a potential antide-
pressant (Lu et al., 2006), and as a biomarker in breast cancer
progression (Artac and Altundag, 2012). The possible involve-
ment of leptin in autoimmune diseases such as multiple scle-
rosis (De Rosa et al., 2007), rheumatoid arthritis (Otvos et al.,
2011), and autoimmune hepatitis (Sennello et al., 2005), and
in cancer (Otvos et al., 2011), has raised therapeutic interest
in leptin and LR antagonists.
The LR ectodomain (LRecto) comprises two cytokine receptor
homology domains (CRH1 and CRH2) flanking an immuno-
globulin (Ig)-like motif, followed by two membrane-proximal
fibronectin type III (FNIII) domains (Figure 1A). A single-helix
transmembrane domain connects LRecto to the intracellular seg-
ments, which carry the conserved juxtamembrane motifs box1
and box2 for binding of JAKs (Ghilardi and Skoda, 1997). The
CRH2 domain is responsible for leptin binding (Fong et al.,
1998; Iserentant et al., 2005; Peelman et al., 2004), while the
Ig-like domain is required for receptor activation (Zabeau et al.,
2004). Whereas LR has been classified as a type 1 cytokine
receptor because of the presence of conserved WSXWS
sequence motifs in such receptors, it exhibits a number of
distinct organizational features suggesting that it may employ
unique assembly and mechanistic principles. For instance, LR
does not recruit a coreceptor in the signaling complex, it can
undergo ligand-independent oligomerization at the cell surface,
it has multiple isoforms that may assemble as hetero-oligomers
(Bacart et al., 2010), the N-terminal CRH1 segment has a hitherto
unidentified role in receptor activation, and LRecto harbors an un-
precedented combination of CRH, Ig-like, and FNIII domains.
These architectural eccentricities are manifested at the mecha-
nistic level as well, which is not well understood but was shown
to involve preoligomeric receptors at the cell surface (Biener
et al., 2005; Couturier and Jockers, 2003) that upon leptints reserved
Figure 1. Biochemical and Structural Characterization of LRecto
(A) Schematic representation of LR. LRecto has five functional domains: distal
NTD (sepia), CRH1 (red), Ig-like domain (violet), and CRH2 (orange), followed
by two membrane-proximal FNIII domains (green).
(B) FFF-MALS analysis of LRecto.
(C) Model for LRecto based on restrained rigid-body refinement based on
SAXS data.
(D) Comparison of calculated X-ray scattering (green) from the rigid-body
model of LRecto against the experimental scattering data (black).
(E) Western blot analysis of full-length LR showing the absence of covalent
dimers at the cell surface.
See also Figures S1 and S5.
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Mechanistic Paradigm of Leptin Receptor Activationbinding may oligomerize further to form a signaling-competent
complex of higher order (Zabeau et al., 2004).
Homology-based structural analysis of leptin, a monomeric
cytokine that adopts a four-helix bundle fold (Zhang et al.,
1997), complemented by mutagenesis studies led to proposals
for three distinct binding sites on leptin (Iserentant et al., 2005;
Niv-Spector et al., 2005; Peelman et al., 2004, 2006). The canon-
ical site II interacts with the CRH2 domain on LR and is essential
for high-affinity binding, while site III interacts with the Ig-like
domain on LR and likely invokes conformational changes neces-
sary for signal transduction. On the other hand, the role of puta-
tive binding site I has been rather controversial because of the
lack of robust mutagenesis and functional data to fully substan-
tiate its importance. The relevance of site III of leptin has inspired
the design of leptin variants with potent antagonistic properties
(Gertler, 2006; Peelman et al., 2004), whereby the leptin variants
retain their ability to interact with LR but are unable to sup-
port signaling. Besides their therapeutic potential, such leptin
variants could serve as excellent tools to probe structural and
mechanistic aspects of leptin-LR signaling.
Despite great progress in our understanding of the structural
basis of several extracellular signaling assemblies mediated byStructure 22,type I cytokine receptors such as the interleukin-6 receptor
(IL-6R) (Boulanger et al., 2003; Skiniotis et al., 2005), the inter-
leukin-2 receptor and interleukin-15 receptor (Ring et al., 2012;
Wang et al., 2005), and the granulocyte macrophage colony-
stimulating factor receptor (Hansen et al., 2008), our view of
leptin-LR complexes and the mechanism of LR activation has
not yet come to full circle despite recent developments
(Carpenter et al., 2012; Mancour et al., 2012). We here employ
structural, biophysical, biochemical, and cellular studies to study
the assembly and mechanistic principles of mouse LR in com-
plex with wild-type leptin (wt-leptin) and leptin variants with
antagonistic properties. In light of a wealth of prior studies, we
have arrived at a mechanistic proposal for the assembly of
leptin-LR signaling complexes, which can now serve as a
working paradigm for future mechanistic interrogation of leptin-
mediated signaling.
RESULTS
LRecto Adopts a Monomeric Extended Structure
To enable structural and biophysical studies of the LRecto and its
complexes with leptin and leptin antagonists, we expressed
LRecto (N-terminal domain [NTD], CRH1 domain, Ig-like domain,
CRH2 domain, and tandem FNIII domain) (Figure 1A) in tran-
siently transfected human embryonic kidney 293T (HEK293T)
cells in the presence of the mannosidase inhibitor kifunensine
(Chang et al., 2007) as a recombinant protein construct carrying
a C-terminal hexahistidine tag. LRecto purified via immobilized
metal-ion affinity chromatography and size-exclusion chroma-
tography (SEC) could be characterized as a monodisperse
species using multiangle laser light scattering (MALS) after
sample resolution via field-flow fractionation (FFF) consistent
with monomeric glycosylated LRecto (Figure 1B). In addition, we
investigated the possible role of glycosylation in the oligomeriza-
tion propensity of LRecto by expressing LRecto in stably trans-
fected human embryonic kidney 293S (HEK293S) GnTI/ cells
producing LRecto with homogeneous N-linked GlcNAc2Man5
glycans and found that it retains its monomeric character.
We subsequently undertook structural studies of LRecto in
solution by small-angle X-ray scattering (SAXS). In the first
instance, this allowed us to probe the oligomerization tendency
of LRecto within a broad range of concentrations up to 17 mM
(3.1 mg/ml) (Table 1; Figure S1A available online). To facilitate
structural modeling of the SAXS data, we first constructed
models of LRecto on the basis of structure-based sequence
alignments, homology modeling, and structure-prediction
approaches. Our initial strategy was based on ab initio modeling
approaches (Franke and Svergun, 2009) and restrained rigid-
body refinement protocols (Petoukhov and Svergun, 2005) but
failed to lead tomodels showing good agreement with the exper-
imental data. Given that LRecto was shown to have 16 N-linked
glycosylation sites (Haniu et al., 1998), we expanded our
approach to include modeling of oligomannose glycan trees
(Bohne-Lang and von der Lieth, 2005) and treated them as indi-
vidual rigid-body entities with appropriate restraints to LRecto.
We had previously applied a similar approach to structurally
characterize large and flexible glycosylated cytokine receptor
complexes (Elegheert et al., 2012; Felix et al., 2013). Our struc-
tural analysis of LRecto showed that LRecto adopts a monomeric866–877, June 10, 2014 ª2014 Elsevier Ltd All rights reserved 867
Table 1. SAXS Analysis of LRecto and wt-Leptin/LRecto Quaternary and Binary Complexes
Parameter LRecto wt-Leptin/LRecto Quaternary Complex wt-Leptin/LRecto Binary Complex
Data Collection Parameters
Beamline ID 14-3, ESRF SWING, SOLEIL SWING, SOLEIL
Detector PILATUS 1M AVIEX PCCD AVIEX PCCD
Beam geometry (mm2) 0.7 3 0.7 0.45 3 0.04 0.45 3 0.04
Wavelength (A˚) 0.931 1.54 1.54
q range (A˚1) 0.15–6.11 0.06–6.12 0.06–6.12
Exposure time (s) 100 (10 3 10) 1 1
Concentration range (mg/ml) 0.9–3 10 (injected) 10 (injected)
Temperature (K) 293 293 293
Structural Parameters
I0 (A˚
1) (from P[r]) 151.6 ± 4.3 0.137 0.067
Rg (A˚) (from P[r]) 65.4 ± 0.3 87.0 63.9
I0 (A˚
1) (from Guinier) 151.3 ± 1.4 0.137 0.067 ± 0.0
Rg (A˚) (from Guinier) 63.8 ± 1.6 84.9 61.9 ± 0.2
Dmax (A˚) 219.2 ± 0.7 297.1 216.7
Porod volume estimate, Vr (A˚
3) 244,025 1,225,451 463,936
Excluded volume, Vex (A˚
3) 346,000 1,450,000 608,000
Molecular Mass (kDa)
From I0 146.4 ± 4.2 305 149.1
From SAXSMoW 138.5 — —
Protein sequence (Protparam) 93 218 109
Protein sequence + N-glycans 124 280 140
Modeling Parameters
Symmetry P1 P2 P1
c2 of reference model 1.1 1.2–1.3 1.3
Number of models averaged 20 20 28
DAMAVER NSD (var) 0.808 ± 0.025 — —
Rigid body modeling SASREF SASREF SASREF
Initial c2 1.2 17.4 4.6
Final c2 1.2 2.2 3.5
Software/Server
Data reduction BSX-CUBE FOXTROT FOXTROT
Data processing PRIMUS PRIMUS-QT PRIMUS-QT
Data evaluation PRIMUS/GNOM PRIMUS-QT/GNOM PRIMUS-QT/GNOM
Structure modeling (ab initio) DAMMIF DAMMIF DAMMIF
Structure modeling (rigid body) SASREF/EOM SASREF SASREF
Structure
Mechanistic Paradigm of Leptin Receptor Activationand extended structure measuring803 803 225 A˚ that is hall-
marked by an elbow bend centered at the Ig domain (Figures 1C
and 1D; Figure S1B). The N-terminal CRH1 segment can be
described by three structural domains, followed by the Ig
segment, a CRH2 segment with two domains, and ending with
two FNIII domains. A parallel structural study of LRecto via nega-
tive-stain electron microscopy (EM), albeit at inherently much
lower sample concentrations, led to class averages bearing
features closely resembling the structural models obtained via
SAXS (Figure S1C).
Our finding that LRecto lacks inherent dimerization propensity
even at such high concentrations came as a surprise because
of previous reports that LR exists in a dimeric form at the cell
surface (Biener et al., 2005; Devos et al., 1997; White and Tarta-868 Structure 22, 866–877, June 10, 2014 ª2014 Elsevier Ltd All righglia, 1999) and that such predimerized assemblies might be
mediated by disulfide bridges between LR molecules (Zabeau
et al., 2005). In addition, we had also observed that shorter con-
structs of the extracellular segment of LR (LRCRH1-Ig-CRH2 or LRIg-
CRH2) showed the tendency to form covalent oligomers. To
cross-validate the possible role of covalent receptor-receptor
interactions, we selectively captured LR at the cell surface
labeled with sulfo-NHS-SS-biotin in the presence of iodoaceta-
mide, followed by detection via western blotting. Our analysis
showed LR as a single band corresponding to the monomeric
molecular weight (Figure 1E), thereby establishing the noncova-
lent character of LR at the cell surface. Thus, in the absence of
any inherent oligomerization propensity in LRecto, dimerization
of LR at the cell surface is likely driven by the transmembranets reserved
A B C Figure 2. Biochemical and Biophysical
Characterization of wt-Leptin/LRecto Com-
plexes
(A) FFF-MALS analysis of wt-leptin/LRecto com-
plexes consistent with 1:1 (blue) and 2:2 (red)
stoichiometries.
(B) ITC thermograms of wt-leptin binding to LRecto
at concentrations that sustain a 1:1 stoichiometric
complex.
(C) ITC thermograms of wt-leptin binding to LRecto
at concentrations that sustain formation of a 2:2
stoichiometric complex.
See also Figure S2.
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Mechanistic Paradigm of Leptin Receptor Activationand intracellular segments of the receptor and may be enhanced
by the dimensionality of the membrane (Wu et al., 2011). In this
regard, earlier studies investigating constitutive LR dimers at
the cell surface demonstrated that the short form of LR lacking
the intracellular segment was still able to form constitutive
dimers (Biener et al., 2005) and that constitutive dimers consist-
ing of full-length LR are far more stable than LR lacking the intra-
cellular segment (Couturier and Jockers, 2003).
Leptin and LRecto Engage in a Noncovalent Quaternary
Complex with 2:2 Stoichiometry
We used several lines of experimentation to characterize binding
of leptin to LRecto and to obtain structural insights into the
assembly of extracellular leptin:LRecto complexes. Incubation
of purified recombinant LRecto with a molar excess of leptin,
followed by chromatographic analysis by SEC, typically resulted
in two incompletely resolved peaks: a minor high molecular
weight peak and a major low molecular weight peak. This sug-
gested that the leptin-LRecto complex might be a dynamic equi-
librium of high and lowmolecular weight complexes, with dilution
favoring the low molecular weight species. To better charac-
terize these two possible states, we subjected assembled
leptin-LRecto complexes to MALS-FFF analyses and found that
the two assemblies are consistent with a binary 1:1 stoichiom-
etry and a quaternary 2:2 complex, respectively (Figure 2A).
Subjecting complexes with 2:2 stoichiometry to a new round of
SEC resulted in partial dissociation of the 2:2 species to the
1:1 stoichiometric assembly, indicating the concentration
dependence of the assemblies in vitro. Both types of stoichio-
metric complexes could be further stabilized by crosslinking
with formaldehyde (Leitner et al., 2010) and isolated by SEC,
resulting in better preparative resolution of the two candidate
molecular assemblies.
In light of these findings, we sought to characterize the ther-
modynamic and stoichiometric profile of the leptin-LR interac-
tion by isothermal titration calorimetry (ITC). Our approach
centered on carrying out measurements at concentrations that
would be representative of those required to maintain the two
apparent types of complexes we could identify chromatograph-
ically (Figures 2B and 2C). To confirm this, we fractionated the
post-ITC protein solutions by SEC and obtained elution profiles
that cross-validated the exclusive presence of binary 1:1 com-
plex in the ITC titration at low concentration (Figure S2A). On
the other hand, the post-ITC solution at high concentrationStructure 22,resolved as a mixture of complexes with 2:2 and 1:1 stoichiom-
etries (Figure S2B), confirming that a 2:2 stoichiometry is the
maximum attainable for the leptin-LRecto complex. Our ITC mea-
surements show that the 1:1 leptin-LRecto interaction is enthalpi-
cally driven and has an equilibrium dissociation constant (KD) of
13 nM (Figure 2B). Surprisingly, the leptin-LRecto quaternary
complex with 2:2 stoichiometry appears to assemble according
to a similar thermodynamic profile (Figure 2C), which in the first
instance would discount the notion of a positively cooperative
quaternary assembly.
Structural Studies of Leptin in Complex with LRecto
To obtain structural insights into the assembly principles of the
leptin-LRecto complex, we used structural studies by SAXS,
which in the first instance served as an orthogonal method for
corroborating the molecular sizes of the two apparent stoichio-
metric complexes of leptin-LRecto with 1:1 and 2:2 stoichiome-
tries (Table 1). Initial ab initio modeling of SAXS data measured
from crosslinked leptin-LRecto complex with 2:2 stoichiometry
(Figure 2A) revealed pronounced features consistent with a
particle obeying two-fold symmetry. Indeed, application of P2
symmetry in rigid-body refinement protocols produced the
best agreement with the experimental data and revealed a fron-
tally Y-shaped assembly measuring 225 3 300 3 160 A˚
composed of two 1:1 leptin-LRecto subcomplexes (Figure 3A,
curve (i), and Figure 3B; Figure S3). In a given 1:1 subcomplex,
a leptin molecule binds to the CRH2 domain of LRecto, consistent
with what has been termed a site II binding epitope (Peelman
et al., 2004), invoking a drastically different conformational state
of LRecto compared with its unbound state. The apparent conse-
quence of such restructuring in LRecto is that the Ig domain be-
comes primed to associate with a leptin molecule in the second
1:1 subcomplex to establish a site III binding epitope on leptin
(Peelman et al., 2006). Furthermore, the two N-terminal CRH1
segments and the two membrane-proximal FNIII domains
extend away from the core of the complex without engaging in
homotypic receptor interactions. We note that accounting for
16 N-linked GlcNAc2Man9 glycans greatly improved model
agreement with the scattering data, as recently shown for other
receptors (Felix et al., 2013; Guttman et al., 2013). Because
attempts to probe structural flexibility in the glycosylated
leptin-LRecto quaternary complex via the ensemble optimization
method (EOM) (Bernado´ et al., 2007) failed, most likely because
of the unusually large number of degrees of freedom arising from866–877, June 10, 2014 ª2014 Elsevier Ltd All rights reserved 869
Figure 3. Structural Characterization of wt-Leptin/LRecto Complexes by SAXS
(A) Scattering curves calculated from rigid-body models of wt-leptin/LRecto quaternary complex (red) and binary complex (blue) fitted against experimental SAXS
curves of quaternary (i) and binary complex (ii), respectively.
(B) Rigid-body model of the wt-leptin/LRecto quaternary complex derived from SAXS data. Leptin is shown as gray cylinders and LRecto in cartoon and surface
views.
(C) LRecto domain flexibility in the wt-leptin/LRecto quaternary complex revealed from a superposition of the 50 best models of the complex (c
2 = 2.2–2.7) derived
via restrained rigid-body modeling of SAXS data. The best model is colored in pink and all other models in a gradient of blue, with darker blue representing better
fitting models.
(D) Rigid-body model for the wt-leptin/LRecto binary complex derived from SAXS data.
(E) Pairwise distance-distribution plot of relative probability versus distance for LRecto (green) and wt-leptin/LRecto binary (blue) and quaternary (red) complexes.
See also Figures S3 and S5.
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Mechanistic Paradigm of Leptin Receptor Activationthe combination of more than 20 rigid bodies, we resorted to an
alternative approach instead. Parallel modeling runs via
restrained rigid-body refinement protocols implemented in
SASREF and superimposition of the best 50 models confirmed
an overall high degree of consistency in the models obtained
and allowed us to assess the global structural flexibility and
modularity of the complex (Figure 3C). Although the refined con-
formations for LRCRH2-Ig and leptin agree well in the collection of
models, suggesting only moderate flexibility in the core of the
complex, the relatively poor alignment in the extremities of the
complex defined by LRCRH1 and LRFNIII suggested a much
greater degree of flexibility in these regions. Nonetheless, the
conformational clustering of this group of models within a narrow
range of c2 values would be consistent with an ensemble of
conformers (Figure 3C). Upon extrapolating our structural
studies to characterize the leptin-LRecto complex obeying 1:1
stoichiometry (Figure 3A, curve (ii), and Figure 3D) we found
that this binary complex adopts a conformation that is quite
different from its structure in the quaternary complex and that
of unbound LRecto, as further supported by comparisons of the
pair-distance distribution functions (Figure 3E).870 Structure 22, 866–877, June 10, 2014 ª2014 Elsevier Ltd All righAntagonist Leptin Variants Abrogate Ligand-Induced LR
Oligomerization
Given the capacity of leptin to engage LRecto into 2:2 stoichio-
metric complexes, we pursued biochemical and structural
insights into the possiblemodeof antagonismby two established
antagonist leptin variants (Niv-Spector et al., 2005; Peelman
et al., 2004). A parallel reasoning was that by studying LR antag-
onism,wemight be able to obtain additionalmechanistic insights
into the assembly of cognate ligand-receptor complexes. One of
the antagonists employed (leptina1) carries a S120A/T121A
double mutation localizing at the beginning of helix D (Peelman
et al., 2004) and was designed to interrogate the relevance of
site III on leptin, while the second (leptina2) bears a substitution
39AAAA42 in the loop linking helices A and B and was proposed
to influence the leptin-LRIg interaction (Niv-Spector et al., 2005).
We note that the two sets ofmutations cluster close to each other
on the leptin scaffold, as the AB loop traverses the start of helix D.
Analyses by SEC-MALS of leptina1-LRecto and leptina2-LRecto
complexes revealed that in contrast to wt-leptin, the two
antagonist leptin variants are only able to engage LRecto in a
complex obeying 1:1 stoichiometry (Figure 4A). Interestingly,ts reserved
AB
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Figure 4. Biophysical and Structural Characterization of Leptina1/LRecto and Leptina2/LRecto Complexes
(A) SEC-MALS of leptina1/LRecto and leptina2/LRecto complexes.
(B) ITC thermograms of leptina1 and leptina2 binding to LRecto.
(C) Plot of theoretical scattering intensity from rigid-body models of leptina1/LRecto (orange) and leptina2/LRecto (violet) fitted to the experimental scattering (black)
from the respective complexes.
(D) Rigid-body models of leptina1/LRecto and leptina2/LRecto binary complexes. The color scheme is as in Figure 3.
(E) Pairwise distance distribution plot of relative probability versus distance for LRecto (green), leptina1/LRecto (orange), leptina2/LRecto (red), and binary complex of
wt-leptin/LRecto (dotted blue).
(F) Class averages of leptina2/LRecto as revealed by negative-stain EM (left). Shown are five class averages of a total of seven (about 50 particles averaged per
class) selected from a total of 391 particles. Also shown to the right of each class average is the ab initio model from SAXS in comparable orientation.
See also Figures S4 and S5.
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Mechanistic Paradigm of Leptin Receptor Activationthe thermodynamic binding fingerprints for both antagonists
(Figure 4B) are very similar to that for wt-leptin (Figure 2B), sug-
gesting that the driving force for the assembly of the wt-leptin
complex with LRecto is the interaction with LRCRH2 via site II.
Structural modeling of the two binary complexes via ab initio
and rigid-body modeling of SAXS data (Figures 4C–4E; Fig-
ure S4; Table 2) and leptina2-LR via negative-stain EM (Figure 4F)
led to molecular complexes that strongly resemble the binary
complex of wt-leptin with LRecto in 1:1 stoichiometry (Figure 3D),
as further evidenced by comparisons of the pairwise distance
distribution function (Figure 4E). Thus, we can now confirm that
leptina1 does target site III of leptin and that leptina2 also appears
to behave as a site III antagonist, thereby pointing to the mech-
anistic importance of this interaction in mediating agonist-
induced LR dimerization.
Free Cysteines in LRecto May Constitute Conformational
Switches for Activation
Delineation of the disulfide-bond network in human LRecto has
shown that LRecto carries ten free cysteines (Haniu et al.,Structure 22,1998). Six of these are conserved in mouse LRecto, and at least
one of them, Cys672, found in the membrane proximal FNIII
domain, was shown to be essential for receptor activation
(Zabeau et al., 2005). Interestingly, the recent crystal structure
of LRCRH2 in complex with a Fab fragment (Carpenter et al.,
2012) provided insights leading to the proposal that a Cys604-
Cys672 intrareceptor disulfide might be important for receptor
activation. In this study, we mutated Cys604 in LRCRH2 close to
the LRCRH2-LRFNIII domain boundary to serine and found that
themutant receptor can be activated only at very high leptin con-
centrations (>500 ng/ml), as measured by rat pancreatitis asso-
ciated protein 1 (rPAP1)-luciferase reporter activity. Thus, both
Cys604 and Cys672 appear to be important for receptor activa-
tion. We further note that our refined model for the 2:2 leptin-
LRecto complex (Figure 3) does not foster any restraints for the
coupling of Cys604 and Cys672 into a disulfide at the interface
of the CRH2 domains, and yet the two CRH2 domains refine to
positions that allow Cys604 and Cys672 to face each other
poised for such an interaction. To extend these studies and to
obtain insights into the general relevance of unpaired cysteines866–877, June 10, 2014 ª2014 Elsevier Ltd All rights reserved 871
Table 2. SAXS Analysis of LRecto in Complex with the Leptin
Antagonists Leptina1 and Leptina2
Parameter
Leptina1/LRecto
(Binary Complex)
Leptina2/LRecto
(Binary Complex)
Data Collection Parameters
Beamline ID 14-3, ESRF ID 14-3, ESRF
Detector PILATUS 1M PILATUS 1M
Beam geometry (mm2) 0.7 3 0.7 0.7 3 0.7
Wavelength (A˚) 0.931 0.931
q range (A˚1) 0.15–6.11 0.15–6.11
Exposure time (s) 100 (10 3 10) 100 (10 3 10)
Concentration range (mg/ml) 0.9–2.7 0.7–7.5
Temperature (K) 293 293
Structural Parameters
I0 (A˚
1) (from P[r]) 145.9 ± 6.2 35.7 ± 2.4
Rg (A˚) (from P[r]) 69.1 ± 0.7 68.6 ± 2.8
I0 (A˚
1) (from Guinier) 146.1 ± 6.5 51.0 ± 3.6
Rg (A˚) (from Guinier) 67.7 ± 0.8 67.0 ± 3.8
Dmax (A˚) 236.4 ± 0.3 234.0 ± 1.5
Porod volume estimate, Vr (A˚
3) 286,541 273,948
Excluded volume, Vex (A˚
3) 372,000 390,000
Molecular Mass (kDa)
From I0 140.9 ± 6.0 155.1 ± 10.5
From SAXSMoW 164.9 151.7
Protein sequence (Protparam) 109 109
Protein sequence + N-glycans 140 140
Modeling Parameters
Symmetry P1 P1
c2 of reference model 1.3 0.8
Number of models averaged 20 20
DAMAVER NSD (var) 1.02 ± 0.06 0.82 ± 0.05
Initial c2 3.3 0.9
Final c2 2.5 0.9
Software/Server
Data reduction BSX-CUBE BSX-CUBE
Data processing PRIMUS PRIMUS
Data evaluation PRIMUS, GNOM PRIMUS, GNOM
Structure modeling (ab initio) DAMMIF DAMMIF
Structure modeling (rigid body) SASREF SASREF
Structure
Mechanistic Paradigm of Leptin Receptor Activationin the conformational competence of LRecto toward complex for-
mation, we alkylated the free cysteines in LRecto using iodoace-
tamide. We discovered that although the acetylated receptor
could readily form a 1:1 complex with leptin, it lost its ability to
undergo leptin-dependent dimerization to form a 2:2 quaternary
complex (Table S1 and Figure S5). These alkylated binary com-
plexes bear striking resemblance to the binary complexes of
leptin and antagonist leptin variants (Figures 3D and 4D).
Together, these lines of evidence show that Cys604 and
Cys672 are likely candidates in engaging into an intrareceptor
disulfide in the context of a leptin-LR quaternary complex and
receptor activation. Indeed, recent evidence for functionally rele-
vant redox regulation of the common gc receptor was reported in872 Structure 22, 866–877, June 10, 2014 ª2014 Elsevier Ltd All righthe context of interleukin-2 mediated signaling (Metcalfe et al.,
2012). We expect that these insights will inspire future studies
to delineate the role of unpaired cysteines in LRecto in receptor
activation.
DISCUSSION
The principles underlying the assembly of the leptin-mediated
extracellular signaling complex of LR have remained unclear
despite great advances in understanding the physiology and
biomedical relevance of signaling along the leptin-LR axis
(Ando` and Catalano, 2012; Guo et al., 2012). Receptor oligomer-
ization culminating with receptor activation is a well-established
paradigm for many type I cytokine receptors, but the role of the
activating ligand varies among receptors. Although growth hor-
mone receptor (Gent et al., 2002) and erythropoietin receptor
(Livnah et al., 1999) exist as inactive dimers at the cell surface
that are activated upon ligand binding, others, such as IL-6Ra/
gp130 (Boulanger et al., 2003), leukemia inhibitory factor recep-
tor (Huyton et al., 2007), and granulocyte macrophage colony-
stimulating factor receptor (Hansen et al., 2008) proceed via
ligand-induced receptor oligomerization coupled to concomitant
conformational changes. LR has been reported to exist as a
dimer or oligomer at the cell surface (Bacart et al., 2010; Biener
et al., 2005; Devos et al., 1997; White and Tartaglia, 1999), but
the conformational impact of leptin binding in the assembly of
signaling complexes has remained unclear.
In this study, we used diverse methods and molecular tools,
including two established leptin antagonists, to provide struc-
tural and mechanistic insights into this process that now add
to recent developments in the field (Carpenter et al., 2012;
Mancour et al., 2012). By carrying out comparative studies of
wild-type and antagonist leptins, we have shown that high-
affinity binding of leptin to the CRH2 domain of LRecto leads to
structural rearrangements in LRecto to prime assembly of a com-
plex obeying 2:2 stoichiometry. This is mediated by an interac-
tion interface between leptin participating in a given leptin:LRecto
binary complex with the Ig domain of LRecto in a second 1:1 com-
plex. Contrary to other modular cytokine-receptor complexes of
similar size and complexity (Lupardus et al., 2011; Skiniotis et al.,
2005; Verstraete and Savvides, 2012), the leptin-LRecto quater-
nary complex lacks homotypic receptor interactions. Although
our binding studies revealed that both 1:1 and 2:2 complexes
assemble via similar thermodynamic binding profiles and affin-
ities, we expect that the likely decrease in the number of degrees
of freedom due to the dimensionality of the cell membrane may
greatly affect the thermodynamics and kinetics of the invoked
interaction between site III on leptin and LRIg in a cellular context
(Wu et al., 2011). In this regard, we have now provided direct
evidence for the importance of this interaction by elucidating
the structural basis of leptin antagonism by two leptin mutants
that stall the leptin-LR interaction to 1:1 stoichiometric com-
plexes. Indeed, the inability of leptina2 to elicit fluorescence reso-
nance energy transfer (FRET) signal elevation when added
to cells expressing LR with intracellular fluorescence tags (Niv-
Spector et al., 2005) is consistent with the concomitant loss of
oligomerization capacity when the functionality of site III is abol-
ished. Furthermore, we have shown that LRecto lacks inherent
dimerization propensity, which now uncouples the role of LRectots reserved
AB
Figure 5. Comparison of SAXS-Derived and EM-Derived Models for
the Leptin-LRecto Quaternary Complex
(A) Comparison of calculated scattering from a bead model derived from the
previously reported EM envelope for the leptin-LRecto quaternary complex
(Mancour et al., 2012) (green) and the present experimental SAXS data for the
leptin-LRecto quaternary complex (raspberry). Inset: Bead model generated
from the EM envelope of wt-leptin/LRecto quaternary complex (green) and
major cluster center of the ab initio models from the SAXS of wt-leptin/LRecto
quaternary complex (raspberry).
(B) Comparison of the SAXS-derived model for the wt-leptin/LRecto quaternary
complex with the envelope for the complex derived by EM (Mancour et al.,
2012).
Figure 6. Proposed Mechanism for LR Activation
LR is preassembled as inactive dimer on the cell membrane (center). Leptin-
induced activation can proceed through a cis-activation or a transactivation
model. In the cis-activation model (left), leptin interacts with the predimerized
receptor to form a 2:2 complex. This process does not require de novo olig-
omerization; only ligand-induced conformational changes within the receptor
dimer lead to the signaling complex. Such a signaling complex model (Man-
cour et al., 2012) is not consistent with previous findings on the requirement for
more than two LR molecules for the formation of the signaling complex (Za-
beau et al., 2004). The transactivation model (right) results from ligand-induced
transdimerization of two preformed LR dimers, forming a 4:4 signaling com-
plex. This model is compatible with the requirement for more than two copies
of LR in a signaling complex (Zabeau et al., 2004). Red circles denote NTD and
red cylinders denote CRH1, purple denotes Ig, orange denotes CRH2, green
denotes FNIII, and gray denotes leptin.
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Mechanistic Paradigm of Leptin Receptor Activationfrom the assembly of constitutive, yet inactive, dimeric or oligo-
meric forms of LR at the cell surface in the absence of ligand
(Bacart et al., 2010; Biener et al., 2005; Devos et al., 1997; White
and Tartaglia, 1999).
The main question arising is whether the observed leptin-
LRecto complex represents a signaling-competent assembly.
An analogous complex derived by EM also obeys a 2:2 stoichi-
ometry and has been proposed as a leptin-LR signaling complex
(Mancour et al., 2012). The latter is conformationally distinct from
the assembly we presented here (Figure 5). Despite the structural
differences between the two assemblies, which as such can be
attributed to inherent methodological limitations calling for vali-
dation via orthogonal methods, it would still be tempting to pro-
pose the observed quaternary complexes as signaling-compe-
tent states. However, we maintain that careful consideration of
previous work in light of our structural data suggests otherwise.
Several studies have established that LR exists predominantly
as a constitutive dimer at the cell surface (Bacart et al., 2010;
Bahrenberg et al., 2002; Biener et al., 2005; Couturier and
Jockers, 2003; Devos et al., 1997; White and Tartaglia, 1999).Structure 22,In addition, quantitative FRET based on acceptor photobleach-
ing and fluorescence lifetime imaging microscopy on single cells
(Biener et al., 2005) had suggested ligand-induced conforma-
tional changes and de novo oligomerization of LR in situ. Thus,
considering constitutive LR dimers as basal assemblies for the
nucleation of signaling complexes and leptin’s ability to dimerize
LRecto in vitro, we propose that the model most consistent with a
higher order assembly would be a complex obeying 4:4 stoichi-
ometry (Figure 6). According to this model, which contrasts
previous proposals (Mancour et al., 2012; Peelman et al.,
2006), binding of leptin to predimerized but inactive LR at the
cell surface induces transdimerization of LR dimers to establish
a signaling-competent complex. Importantly, such an assembly
paradigm would be consistent with the observed weakly domi-
nant negative repression of LR signaling by the short form of non-
signaling LR (Devos et al., 1997; White et al., 1997) in the context
of heteromeric LR dimers at the cell surface (Bacart et al., 2010)
and supports previous studies using JAK-STAT signaling
complementation (Zabeau et al., 2004). Finally, our proposed
mechanistic paradigm further highlights the therapeutic impor-
tance of leptin antagonist variants that can abrogate such
assemblies while displaying near wild-type affinities to LR. We
envisage that the present mechanistic proposal for leptin-medi-
ated activation of LR will set the stage for a more targeted mech-
anistic interrogation of the system as well as renewed efforts in
antagonist development.
EXPERIMENTAL PROCEDURES
Expression and Purification of Recombinant Proteins
HEK293T cells were transiently transfected with pMET7 vector carrying cDNA
for LRecto and were cultured in Dulbecco’s modified Eagle’s medium in the
presence of penicillin (Sigma), streptomycin (Sigma), and the mannosidase
inhibitor kifunensine (Tocris Bioscience) for 4 days at 37C under 5% CO2.
The medium was harvested by centrifugation at 10,000 3 g and filtered using866–877, June 10, 2014 ª2014 Elsevier Ltd All rights reserved 873
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Mechanistic Paradigm of Leptin Receptor Activationa 0.2 mmbottle-top filter. The secreted receptor was captured as a His-tagged
protein on a TALON resin (Clontech), washed with 4 mM imidazole (Sigma
Aldrich), and eluted with 300 mM imidazole. Purified LRecto was pooled and
concentrated to 1 ml and was further purified on a Superdex 200 HiLoad
16/600 column (GE Healthcare) pre-equilibrated with buffer containing
25 mM HEPES (pH 7.4) and 100 mM sodium chloride.
Expression constructs for wt-leptin, antagonist leptina1 (carrying a
S120A/T121A double mutation), antagonist leptina2 (bearing a substitution
39AAAA42) were established in the pET-11a vector, and the recombinant
proteins were produced in E. coli as inclusion bodies.Washed inclusion bodies
were solubilized in 7 M urea, and recombinant proteins were refolded in vitro
by dialysis to remove urea. This preparation was further purified by ion-
exchange chromatography on an ANX FF column (GE Healthcare) and by
SEC using a HiLoad Superdex75 column (GE Healthcare).
Purified LRecto and wild-type or antagonist leptins were concentrated to 8
and 5 mg/ml, respectively. LRecto was mixed with a 6-fold molar excess of
ligand, and the mixture was incubated at room temperature for 1 hr, followed
by injection onto a pre-equilibrated Superdex 200 HiLoad 16/600 column. In
the case of wt-leptin, the resulting binary and quaternary complex peaks
were pooled separately for further studies.
To prepare alkylated LRecto via its free cysteine sulfhydryls, purified LRecto
was incubated with 5 mM iodoacetamide for 1 hr. Complex formation with
leptin and antagonist leptins was carried out as for unmodified LRecto.
Immunoprecipitation and Western Blot of Full-Length LR at the Cell
Surface
HEK293T cells were seeded and after 1 day were transfected with pMET7
vector encoding murine LR with a C-terminal FLAG tag. After 24 hr, cells
were washed with PBS and cultured further with 10% fetal calf serum (Sigma
Aldrich). For cell-surface biotinylation, cells were detached with trypsin and
washed three times with ice-cold PBS. Cells were resuspended to 25 3 106
cells/ml and treated with 0.1% azide to prevent internalization of cell-surface
receptors. Cells were incubated at room temperature with freshly prepared
0.8 mM sulfo-NHS-SS for 30 min. To remove unreacted biotin, cells were
washed with ice-cold PBS containing 0.1% azide. Cells were lysed using
modified radioimmunoprecipitation assay buffer containing 50mM iodoaceta-
mide, to prevent nonphysiological clustering during processing, and lysate
was cleared by centrifuging for 10 min at 14,000 rpm. To enrich biotinylated
LR using Dymabeads Streptavidin T1 (Invitrogen), beads were washed three
times with PBS, cleared lysate was added to the beads, and the mixture
was incubated at room temperature for 30minwhile rotating andwashed three
times with PBS containing 0.1% (v/v) Tween-20 (Sigma). Biotinylated LR was
eluted with Laemmli buffer. For detection, samples were heated at 65C for
5 min and resolved on 7.5% SDS-PAGE with and without 2-mercaptoethanol.
LR was detected via western blot using an anti-FLAG antibody (Sigma).
Chemical Crosslinking of LRecto/wt-Leptin Complex
Thirty microliters of 36.5% to 38% aqueous solution of formaldehyde (Sigma)
was diluted in 1 M HEPES (pH 7.4) to a final volume of 100 ml. Then 5 ml of this
diluted formaldehyde was added to 40 ml of wt-leptin/LRecto quaternary com-
plex at 0.3 to 0.8 mMand adjusted to a final volume of 50 ml with buffer contain-
ing 50 mM HEPES (pH 7.4) and 100 mM sodium chloride, followed by a 3 hr
incubation at room temperature. The crosslinking reaction was stopped by
adding 1 M Tris (pH 7.4). This sample was further analyzed on nonreducing
SDS-PAGE, followed by silver staining to assess the efficiency of crosslinking.
ITC
All protein components were purified in 25 mM HEPES (pH 7.4) containing
100 mM sodium chloride and degassed immediately before titration. Then
20 mM of wt-leptin was titrated against 1.4 ml of 1 mM LRecto with 17 discrete
injections (3 ml followed by 10 ml each) at 37C and mixing at 307 rpm stirring
speed. The heat released was recorded using a MicroCal VP-ITC setup (GE
Healthcare) and analyzed usingOrigin (OriginLab). The best fitting of the exper-
imental data were obtained using a ‘‘one set of sites’’ curve fitting model in
Origin, and this fit was used to determine the equilibrium dissociation constant
(KD), the stoichiometry of the interaction (N), and the enthalpy change (DH). The
change in Gibbs free energy (DG) was calculated using the equation DG =RT
ln (1/KD), and the entropy change (DS) was calculated as DG = DH – TDS.874 Structure 22, 866–877, June 10, 2014 ª2014 Elsevier Ltd All righSimilar experiments were performed for leptina1 and leptina2 to characterize
their interactions with LRecto. In order to verify the stoichiometry of the high
molecular weight complex, a similar protocol was followed using a MicroCal
ITC200 instrument by titrating wt-leptin at 2.4 mg/ml (148 mM) into LRecto at
1.2 mg/ml (8.4 mM).
Binding and Signaling Properties of LRC604S
Cys604 in mouse LR was mutated into a serine using standard site-directed
mutagenesis techniques and was cloned into the pMET7 expression vector.
pMET7-LRC604S was transfected together with the pXP2d2-rPAP1-luciferase
reporter (Eyckerman et al., 2000) into HEK293T cells with calcium phosphate.
Cells were stimulated overnight with a serial dilution of leptin and lysed, and
light emission was measured in a TopCount chemiluminescence counter
(PerkinElmer). Leptin binding was determined using the leptin-secreted
alkaline phosphatase chimera, as described earlier (Zabeau et al., 2005). In
brief, transfected cells are incubated with fusion-protein for 2 hr. After three
washing steps, bound enzymatic activity is measured with the Phospha-Light
assay (Life Technologies) in the TopCount counter.
MALS
The molecular masses, oligomerization state of LRecto, and its complexes with
wt-leptin, leptina1, and leptina2 in a concentration range of 18 to 50 mM were
estimated using MALS. Purified protein samples were resolved on an asym-
metric FFF system (Wyatt Technology) encompassing an ultrafiltration mem-
brane (Microdyn-Nadir) with a 10 kDa cutoff and a spacer with a height of
350 mm, a high-performance liquid chromatography (HPLC) unit (Shimadzu),
an online UV detector (Shimadzu), a static light scattering detector (DAWN
HELEOS), and a refractometer (Optilab T-rEX; Wyatt Technology). To enhance
peak resolution for the wt-leptin/LRecto complex during FFF elution, the cross-
flow was optimized. On the basis of the measured Rayleigh scattering at
different angles and the established differential refractive index increment of
0.185 mL/g for proteins in solution with respect to the change in protein
concentration (dn/dc) (Graupner et al., 1999), weight-averaged molar masses
for each species were calculated using ASTRA V software.
SAXS
Data Collection and Processing
SAXS data were measured at beamline SWING at SOLEIL Synchrotron
(Gif-sur-Yvette, France) with amounted online HPLC system (David and Perez,
2009) and beamline ID14-3 of the European Synchrotron Radiation Facility
(ESRF; Grenoble, France). Purified LRecto and its binary complexes with
leptina1 and leptina2 were measured in bulk mode at 3 different concentrations
in the range of 0.5 to 3 mg/ml. wt-Leptin/LRecto complex at 10 mg/ml was
first resolved on an online gel-filtration column (Shodex KW404-4F). X-ray
scattering data were recorded within a momentum transfer range of
0.01 A˚1 < s < 0.6 A˚1, where s = 4psinq/l. X-ray-induced radiation damage
was evaluated by superposition of ten scattering curves obtained from
integration of continuous radial scattering obtained from independent mea-
surements with 10 s exposure for each sample. For each concentration set,
the scattering data were normalized for beam intensity and exposure time
and corrected for the detector response. Subtraction of buffer scattering
from the sample scattering using PRIMUS (Konarev et al., 2003) eliminated
both buffer background and background arising from instrument hardware.
After resolution of wt-leptin/LRecto on a size-exclusion column, 150 frames
with exposure time of 1 s and delay of 0.5 s each were collected for buffer,
followed by measurements for the protein peak. The forward scattering (I0)
and radius of gyration (Rg) were determined in PRIMUS from infinite dilution
extrapolation on the basis of Guinier approximation and compared with
corresponding estimates from Gnom (Svergun, 1992). The distance dis-
tribution function P(r) and maximal dimension Dmax for each scatterer were
evaluated using Gnom. Molecular masses were calculated on the basis of
the forward scattering from a calibrated sample employing BSA (ID14-3,
ESRF) or water (Swing, SOLEIL) and independent of calibration standards
using SAXSMoW (Fischer et al., 2010). Porod volumes were estimated using
Autoporod (Petoukhov et al., 2012).
Ab Initio Modeling
Three-dimensional shape reconstructions were generated via DAMMIF
(Franke and Svergun, 2009), and 20 models were generated via independentts reserved
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DAMAVER (Volkov and Svergun, 2003). When the average normalized
spatial discrepancy (NSD) value for the 20 models was %1, the set was
considered a single cluster, and the model with the lowest NSD average
value with respect to the other 19 models was considered representative
of the scatterer type. However, for the wt-leptin/LRecto complex, average
NSD values were 1.6. Visual inspection of these models confirmed vari-
ability in the models, possibly because of the flexibility of this system. The
models were clustered using DAMCLUST, and the cluster centers were
considered the representative conformers of the wt-leptin/LRecto quaternary
complex.
Rigid-Body Modeling
Restrained rigid-body refinement of models against the SAXS data was
carried out via SASREF (Petoukhov and Svergun, 2005). The 3D models
for eight individual receptor structural domains (three for CRH1, one for
Ig, two for CRH2, and two for FNIII) were generated as described previously
(Peelman et al., 2006), except for CRH1 and FNIII, which were predicted
using I-TASSER (Roy et al., 2010, 2012). On the basis of the earlier exper-
imental evidence for the sites of glycosylation on LRecto (Haniu et al., 1998)
and further predicted N-glycosylation sites on individual domain predicted
structures, these were glycosylated in silico using GlyProt server (Bohne-
Lang and von der Lieth, 2005). The best results were obtained when two
GlcNAc2Man9 trees (glycan id: 9146) were used for in silico glycosylation.
The distance between Ca atoms of the C and N termini in consecutive
domains was restricted to 3.7 A˚. Initial ligand-receptor and receptor-recep-
tor domain distances were based on the proposed model for the leptin-LR
complex (Peelman et al., 2006) and were optimized in subsequent rounds of
modeling. The quaternary leptin/LRecto complex with 2:2 stoichiometry was
modeled with P2 symmetry restraints, while modeling of all other SAXS data
for LRecto, leptina1-LRecto, and leptina2-LRecto complex was carried out
under P1 symmetry. Model quality was assessed using Crysol (Svergun
et al., 1995).
Negative-Stain EM
Samples were diluted in base buffer (25 mM HEPES [pH 7.4] containing
100 mM sodium chloride) as required and adsorbed for 1 min to glow
discharged thin carbon films coating a perforated carbon layer on gold-coated
copper grids. These were washed with four drops of distillated water and
negatively stainedwith 2% (w/v) uranyl acetate and imagedwith a CM10 trans-
mission electron microscope (Philips) operating at 80 kV. Electron micro-
graphs were recorded with a 2k charge-coupled device camera (Veleta;
Olympus Soft Imaging Solutions) at a nominal magnification of 130,0003,
yielding a final pixel size corresponding to 0.37 nm on the specimen scale.
Particles were manually selected for single-particle analysis and averaged
using EMAN software (Ludtke et al., 1999).
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